Gene expression profiling as a noninvasive method to monitor for cardiac allograft rejection.
SourceTechnology Evaluation Center Assessment Program. Executive summary 26:8 2011 Nov pg 1-3
MeSHBlue Cross Blue Shield Insurance Plans
Gene Expression Profiling
Outcome Assessment (Health Care)
Technology Assessment, Biomedical
United States Food and Drug Administration
Pub Type(s)Journal Article